Anyone who's watched a Viagra commercial knows that Pfizer ($PFE) isn't too embarrassed to talk about sex. Anyone who's run across Pfizer's "Get Old" campaign knows it doesn't shy away from aging, either. Now, the drug giant is going equal opportunity on the sex-and-aging talk, and "Desperate Housewives" actress Brenda Strong has the dialogue. With [...]
(Reuters) - Shares of Auspex Pharmaceuticals Inc soared about 60 percent on Tuesday after the drug developer said its product for treating chorea, or involuntary movement associated with Huntington's disease, met the main goal in a late-stage study. The shares jumped about to $40 in extended trading after closing at $25.09 on Nasdaq. Patients administered [...]
U.S. crude oil prices sold off another 3.3% Monday to the lowest level since July 2009 after OPEC hinted it won't cut its production targets despite swelling supplies. Even though you are paying less at the pump, this is not good for anyone. Plummeting oil, gold, agricultural smells like deflation and deflation is a killer [...]
Tony Coles, the chief executive who sold Onyx Pharmaceuticals to Amgen AMGN -2.45% for $10.4 billion in 2013, is starting a new company that will use yeast to try and discover new treatments for Parkinson’s, Alzheimer’s, and amyotrophic lateral sclerosis (ALS, also known as Lou Gehrig’s disease.) The new startup, Yumanity, will be based in [...]
Teva stalled out? Maybe? Like the rest of the space, TEVA has had a nice ride, but maybe time to step aside. See the article and chart. Don't be surprised if Teva's ($TEVA) revenue numbers don't meet analysts' expectations in 2015. According to the company's forecasts, generic competition to top-seller Copaxone and foreign currency [...]
Drugmakers that complain about the growing cost to bring new molecular entities to market aren’t exaggerating, according to a study released last month by the Tufts Center for the Study of Drug Development (CSDD). Even with the initiation of mechanisms to speed drug development such as breakthrough therapy designation and accelerated review, developing a medicine [...]
When Takeda Pharmaceutical faced the patent-cliff blues, it brought in Christophe Weber as president and COO to engineer a revamp. And true to his mission, Weber unveiled a new org chart in September, along with a fresh set of top managers. Now, Weber has one more seat to fill. The Japanese drugmaker's U.S. president is on his [...]
I normally only post Pharma News, but the railing oil is taking is getting to the danger level. Yes, consumers are happy because they can fill their tank for way less than a few months ago, but plummeting oil screams "deflation", sinking world-wide demand, and huge losses for oil companies and hedge funds. Living in [...]
In partnership with activist investor Bill Ackman, the company made a hostile bid to purchase Botox-maker Allergan. Valeant Pharmaceuticals is putting its acquisition growth strategy on hold in favor of reducing debt and boosting its stock price, according to Reuters. Since 2008, Valeant has spent about $19 billion on 40 acquisitions. Now, the company will [...]
Merck ($MRK) may have to rethink its math on the Cubist ($CBST) buyout. Announcing the $9.5 billion transaction Monday, the company pointed to an earnings bump beginning in 2016. But later in the day, a U.S. court nixed all but one of the patents covering its top seller, Cubicin--and that patent expires in 2016. With [...]
